UK markets close in 25 minutes
  • FTSE 100

    6,414.70
    +80.86 (+1.28%)
     
  • FTSE 250

    19,745.43
    +163.08 (+0.83%)
     
  • AIM

    1,032.89
    -2.15 (-0.21%)
     
  • GBP/EUR

    1.1249
    -0.0003 (-0.03%)
     
  • GBP/USD

    1.3360
    +0.0038 (+0.28%)
     
  • BTC-GBP

    14,459.73
    +613.58 (+4.43%)
     
  • CMC Crypto 200

    382.29
    +12.54 (+3.39%)
     
  • S&P 500

    3,622.10
    +44.51 (+1.24%)
     
  • DOW

    29,978.74
    +387.47 (+1.31%)
     
  • CRUDE OIL

    44.93
    +1.87 (+4.34%)
     
  • GOLD FUTURES

    1,801.80
    -36.00 (-1.96%)
     
  • NIKKEI 225

    26,165.59
    +638.22 (+2.50%)
     
  • HANG SENG

    26,588.20
    +102.00 (+0.39%)
     
  • DAX

    13,294.13
    +167.16 (+1.27%)
     
  • CAC 40

    5,555.94
    +63.79 (+1.16%)
     

Trading in Novo Nordisk shares by board members, executives and associated persons on 3 November 2020

Novo Nordisk A/S
·1-min read

Bagsværd, Denmark, 3 November 2020 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.


Further information

Media:

Mette Kruse Danielsen

+45 4442 3883

mkd@novonordisk.com

Ken Inchausti (US)

+1 609 240 9429

kiau@novonordisk.com

Investors:

Daniel Muusmann Bohsen

+45 3075 2175

dabo@novonordisk.com

Valdemar Borum Svarrer

+45 3079 0301

jvls@novonordisk.com

Ann Søndermølle Rendbæk

+45 3075 2253

arnd@novonordisk.com

Mark Joseph Root

+45 3079 4211

mjhr@novonordisk.com

Kristoffer Due Berg US)

+1 609 235 2989

krdb@novonordisk.com


Company announcement No 66 / 2020

Attachment